Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Применение нестероидных противовоспалительных препаратов и ибупрофена при заболевании COVID-19: систематический обзор
Применение нестероидных противовоспалительных препаратов и ибупрофена при заболевании COVID-19: систематический обзор
Леонова М.В. Применение нестероидных противовоспалительных препаратов и ибупрофена при заболевании COVID-19: систематический обзор. Consilium Medicum. 2020; 22 (12): 31–36. DOI: 10.26442/20751753.2020.12.200558
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Пандемия COVID-19 в настоящее время является наиболее острой проблемой здравоохранения в мире. Несмотря на растущие знания о природе тяжелого острого респираторного синдрома, вызванного SARS-CoV-2, варианты лечения по-прежнему плохо определены. Безопасность нестероидных противовоспалительных препаратов (НПВП), в частности ибупрофена, подвергалась сомнению без каких-либо подтверждающих доказательств. Это способствовало проведению ряда наблюдательных исследований по оценке влияния ибупрофена на исходы заболевания COVID-19. Проведен поиск публикаций и представлен систематический обзор 9 исследований, рассмотрены фармакодинамические эффекты ибупрофена в аспекте влияния на ангиотензинпревращающий фермент 2 (АПФ-2) и циклооксигеназу. Результаты исследований показали отсутствие прямого взаимодействия между ибупрофеном и SARS-CoV-2, отсутствие доказательств того, что ибупрофен влияет на up-регуляцию АПФ-2 как рецептора COVID-19 в исследованиях с участием людей. В наблюдательных исследованиях не получили доказательств, что ибупрофен при хроническом применении до заболевания COVID-19 или при остром применении для купирования симптомов COVID-19 способствует инфицированию или увеличивает риск неблагоприятных исходов (смертность, риск госпитализации, риск искусственной вентиляции легких). Впоследствии международные регуляторные органы (Всемирная организация здравоохранения, Европейское медицинское агентство, Управление по контролю пищевых продуктов и лекарств в США) заключили, что нет связи между более тяжелым течением COVID-19 и лечением НПВП; парацетамол и другие НПВП (ибупрофен) рекомендуются для лечения симптомов COVID-19; пациентов, находящихся на хроническом лечении НПВП, предупреждают, чтобы они не прекращали его, так как их состояние может ухудшиться.
Ключевые слова: COVID-19, нестероидные противовоспалительные препараты, ибупрофен, наблюдательные исследования, смертность.
Key words: COVID-19, non-steroidal anti-inflammatory drugs, ibuprofen, observational studies, mortality.
Ключевые слова: COVID-19, нестероидные противовоспалительные препараты, ибупрофен, наблюдательные исследования, смертность.
________________________________________________
Key words: COVID-19, non-steroidal anti-inflammatory drugs, ibuprofen, observational studies, mortality.
Полный текст
Список литературы
1. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368: m1086. DOI: 10.1136/bmj.m1086
2. Zhang H, Penninger JM, Li Y et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46 (4): 586–90. DOI: 10.1007/s00134-020-05985-9
3. Smart L, Fawkes N, Goggin P et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacology 2020; 28 (5): 1141–52. DOI: 10.1007/s10787-020-00745-z
4. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181 (2): 271–80. DOI: 10.1016/j.cell.2020.02.052
5. Walls AC, Park YJ, Tortorici MA et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181 (2): 281–92. DOI: 10.1016/j.cell.2020.02.058
6. Levy BD, Clish CB, Schmidt B et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2 (7): 612–9. DOI: 10.1038/89759
7. Qiao W, Wang C, Chen B et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 2015; 131 (2): 97–106. DOI: 10.1159/000375362
8. Bancos S, Bernard MP, Topham DJ, Phipps RP. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol 2009; 258 (1): 18–28. DOI: 10.1016/j.cellimm.2009.03.007
9. Graham NM, Burrell CJ, Douglas RM et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990; 162 (6): 1277–82. DOI: 10.1093/infdis/162.6.1277
10. Bruce E, Barlow-Pay F, Short R et al. Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med 2020; 9 (8): 2586. DOI: 10.3390/jcm9082586
11. Imam Z, Odish F, Gill I et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med 2020; 288 (4): 469–76. DOI: 10.1111/joim.13119
12. Jeong HE, Lee H, Shin HJ et al. Association between NSAIDs use and adverse clinical outcomes among adults hospitalized with COVID-19 in South Korea: A nationwide study. Clin Infect Dis 2020; ciaa1056. DOI: 10.1093/cid/ciaa1056
13. Lund LC, Kristensen KB, Reilev M et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med 2020; 17 (9): e1003308. DOI: 10.1371/journal.pmed.1003308
14. Rentsch CT, Kidwai-Khan F, Tate JP et al. Covid-19 testing, hospital admission, and iIntensive care among 2.026.227 United States veterans aged 54–75 years. medRxiv 2020; 2020.04.09.20059964. DOI: 10.1101/2020.04.09.20059964
15. Rinott E, Kozer E, Shapira Y et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect 2020; 26 (9): 1259.e5–7. DOI: 10.1016/j.cmi.2020.06.003
16. Abu Esba LC, Alqahtani RA, Thomas A et al. Ibuprofen and NSAID use in COVID-19 infected patients Is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther 2020; 1–16. DOI: 10.1007/s40121-020-00363-w
17. Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID19 morbidity using electronic health records. medRxiv preprint April 2020. DOI: 10.1101/2020.04.11.20061994
18. Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID19 morbidity using electronic health records. medRxiv 2020: 2020.04.11.20061994. DOI: 10.1101/2020.04.11.20061994
19. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms. https://www.sciencealert.com/whorecommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms
20. Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ 2020; 369: m1555. DOI: 10.1136/bmj.m1555
21. Capuano A, Scaglione F, Berrino L et al. Official statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Nonsteroidal anti-infammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary. Pharmadvances 2020; 2 (1): 6–10. http://www.pharmadvances.com/official-statement-of-the-section-of-clinical-pharmacology-of-italian-s...
22. Zolk O, Hafner S, Schmidt CQ et al. COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. Naunyn Schmiedebergs Arch Pharmacol 2020; 393 (7): 1131–5. DOI: 10.1007/s00210-020-01890-6
23. EMA gives advice on the use of non-steroidal antiinflammatories for COVID-19. EMA/136850/2020. 18 March 2020. https://www.ema.europa.eu/en/documents/press-release/ema-gives-advice-use-non-steroidal-anti-inflamm...
2. Zhang H, Penninger JM, Li Y et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46 (4): 586–90. DOI: 10.1007/s00134-020-05985-9
3. Smart L, Fawkes N, Goggin P et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacology 2020; 28 (5): 1141–52. DOI: 10.1007/s10787-020-00745-z
4. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181 (2): 271–80. DOI: 10.1016/j.cell.2020.02.052
5. Walls AC, Park YJ, Tortorici MA et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181 (2): 281–92. DOI: 10.1016/j.cell.2020.02.058
6. Levy BD, Clish CB, Schmidt B et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2 (7): 612–9. DOI: 10.1038/89759
7. Qiao W, Wang C, Chen B et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 2015; 131 (2): 97–106. DOI: 10.1159/000375362
8. Bancos S, Bernard MP, Topham DJ, Phipps RP. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol 2009; 258 (1): 18–28. DOI: 10.1016/j.cellimm.2009.03.007
9. Graham NM, Burrell CJ, Douglas RM et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990; 162 (6): 1277–82. DOI: 10.1093/infdis/162.6.1277
10. Bruce E, Barlow-Pay F, Short R et al. Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med 2020; 9 (8): 2586. DOI: 10.3390/jcm9082586
11. Imam Z, Odish F, Gill I et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med 2020; 288 (4): 469–76. DOI: 10.1111/joim.13119
12. Jeong HE, Lee H, Shin HJ et al. Association between NSAIDs use and adverse clinical outcomes among adults hospitalized with COVID-19 in South Korea: A nationwide study. Clin Infect Dis 2020; ciaa1056. DOI: 10.1093/cid/ciaa1056
13. Lund LC, Kristensen KB, Reilev M et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med 2020; 17 (9): e1003308. DOI: 10.1371/journal.pmed.1003308
14. Rentsch CT, Kidwai-Khan F, Tate JP et al. Covid-19 testing, hospital admission, and iIntensive care among 2.026.227 United States veterans aged 54–75 years. medRxiv 2020; 2020.04.09.20059964. DOI: 10.1101/2020.04.09.20059964
15. Rinott E, Kozer E, Shapira Y et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect 2020; 26 (9): 1259.e5–7. DOI: 10.1016/j.cmi.2020.06.003
16. Abu Esba LC, Alqahtani RA, Thomas A et al. Ibuprofen and NSAID use in COVID-19 infected patients Is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther 2020; 1–16. DOI: 10.1007/s40121-020-00363-w
17. Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID19 morbidity using electronic health records. medRxiv preprint April 2020. DOI: 10.1101/2020.04.11.20061994
18. Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID19 morbidity using electronic health records. medRxiv 2020: 2020.04.11.20061994. DOI: 10.1101/2020.04.11.20061994
19. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms. https://www.sciencealert.com/whorecommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms
20. Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ 2020; 369: m1555. DOI: 10.1136/bmj.m1555
21. Capuano A, Scaglione F, Berrino L et al. Official statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Nonsteroidal anti-infammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary. Pharmadvances 2020; 2 (1): 6–10. http://www.pharmadvances.com/official-statement-of-the-section-of-clinical-pharmacology-of-italian-s...
22. Zolk O, Hafner S, Schmidt CQ et al. COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. Naunyn Schmiedebergs Arch Pharmacol 2020; 393 (7): 1131–5. DOI: 10.1007/s00210-020-01890-6
23. EMA gives advice on the use of non-steroidal antiinflammatories for COVID-19. EMA/136850/2020. 18 March 2020. https://www.ema.europa.eu/en/documents/press-release/ema-gives-advice-use-non-steroidal-anti-inflamm...
2. Zhang H, Penninger JM, Li Y et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46 (4): 586–90. DOI: 10.1007/s00134-020-05985-9
3. Smart L, Fawkes N, Goggin P et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacology 2020; 28 (5): 1141–52. DOI: 10.1007/s10787-020-00745-z
4. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181 (2): 271–80. DOI: 10.1016/j.cell.2020.02.052
5. Walls AC, Park YJ, Tortorici MA et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181 (2): 281–92. DOI: 10.1016/j.cell.2020.02.058
6. Levy BD, Clish CB, Schmidt B et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2 (7): 612–9. DOI: 10.1038/89759
7. Qiao W, Wang C, Chen B et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 2015; 131 (2): 97–106. DOI: 10.1159/000375362
8. Bancos S, Bernard MP, Topham DJ, Phipps RP. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol 2009; 258 (1): 18–28. DOI: 10.1016/j.cellimm.2009.03.007
9. Graham NM, Burrell CJ, Douglas RM et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990; 162 (6): 1277–82. DOI: 10.1093/infdis/162.6.1277
10. Bruce E, Barlow-Pay F, Short R et al. Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med 2020; 9 (8): 2586. DOI: 10.3390/jcm9082586
11. Imam Z, Odish F, Gill I et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med 2020; 288 (4): 469–76. DOI: 10.1111/joim.13119
12. Jeong HE, Lee H, Shin HJ et al. Association between NSAIDs use and adverse clinical outcomes among adults hospitalized with COVID-19 in South Korea: A nationwide study. Clin Infect Dis 2020; ciaa1056. DOI: 10.1093/cid/ciaa1056
13. Lund LC, Kristensen KB, Reilev M et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med 2020; 17 (9): e1003308. DOI: 10.1371/journal.pmed.1003308
14. Rentsch CT, Kidwai-Khan F, Tate JP et al. Covid-19 testing, hospital admission, and iIntensive care among 2.026.227 United States veterans aged 54–75 years. medRxiv 2020; 2020.04.09.20059964. DOI: 10.1101/2020.04.09.20059964
15. Rinott E, Kozer E, Shapira Y et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect 2020; 26 (9): 1259.e5–7. DOI: 10.1016/j.cmi.2020.06.003
16. Abu Esba LC, Alqahtani RA, Thomas A et al. Ibuprofen and NSAID use in COVID-19 infected patients Is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther 2020; 1–16. DOI: 10.1007/s40121-020-00363-w
17. Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID19 morbidity using electronic health records. medRxiv preprint April 2020. DOI: 10.1101/2020.04.11.20061994
18. Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID19 morbidity using electronic health records. medRxiv 2020: 2020.04.11.20061994. DOI: 10.1101/2020.04.11.20061994
19. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms. https://www.sciencealert.com/whorecommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms
20. Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ 2020; 369: m1555. DOI: 10.1136/bmj.m1555
21. Capuano A, Scaglione F, Berrino L et al. Official statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Nonsteroidal anti-infammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary. Pharmadvances 2020; 2 (1): 6–10. http://www.pharmadvances.com/official-statement-of-the-section-of-clinical-pharmacology-of-italian-s...
22. Zolk O, Hafner S, Schmidt CQ et al. COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. Naunyn Schmiedebergs Arch Pharmacol 2020; 393 (7): 1131–5. DOI: 10.1007/s00210-020-01890-6
23. EMA gives advice on the use of non-steroidal antiinflammatories for COVID-19. EMA/136850/2020. 18 March 2020. https://www.ema.europa.eu/en/documents/press-release/ema-gives-advice-use-non-steroidal-anti-inflamm...
________________________________________________
2. Zhang H, Penninger JM, Li Y et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46 (4): 586–90. DOI: 10.1007/s00134-020-05985-9
3. Smart L, Fawkes N, Goggin P et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacology 2020; 28 (5): 1141–52. DOI: 10.1007/s10787-020-00745-z
4. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181 (2): 271–80. DOI: 10.1016/j.cell.2020.02.052
5. Walls AC, Park YJ, Tortorici MA et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181 (2): 281–92. DOI: 10.1016/j.cell.2020.02.058
6. Levy BD, Clish CB, Schmidt B et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2 (7): 612–9. DOI: 10.1038/89759
7. Qiao W, Wang C, Chen B et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 2015; 131 (2): 97–106. DOI: 10.1159/000375362
8. Bancos S, Bernard MP, Topham DJ, Phipps RP. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol 2009; 258 (1): 18–28. DOI: 10.1016/j.cellimm.2009.03.007
9. Graham NM, Burrell CJ, Douglas RM et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990; 162 (6): 1277–82. DOI: 10.1093/infdis/162.6.1277
10. Bruce E, Barlow-Pay F, Short R et al. Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med 2020; 9 (8): 2586. DOI: 10.3390/jcm9082586
11. Imam Z, Odish F, Gill I et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med 2020; 288 (4): 469–76. DOI: 10.1111/joim.13119
12. Jeong HE, Lee H, Shin HJ et al. Association between NSAIDs use and adverse clinical outcomes among adults hospitalized with COVID-19 in South Korea: A nationwide study. Clin Infect Dis 2020; ciaa1056. DOI: 10.1093/cid/ciaa1056
13. Lund LC, Kristensen KB, Reilev M et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med 2020; 17 (9): e1003308. DOI: 10.1371/journal.pmed.1003308
14. Rentsch CT, Kidwai-Khan F, Tate JP et al. Covid-19 testing, hospital admission, and iIntensive care among 2.026.227 United States veterans aged 54–75 years. medRxiv 2020; 2020.04.09.20059964. DOI: 10.1101/2020.04.09.20059964
15. Rinott E, Kozer E, Shapira Y et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect 2020; 26 (9): 1259.e5–7. DOI: 10.1016/j.cmi.2020.06.003
16. Abu Esba LC, Alqahtani RA, Thomas A et al. Ibuprofen and NSAID use in COVID-19 infected patients Is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther 2020; 1–16. DOI: 10.1007/s40121-020-00363-w
17. Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID19 morbidity using electronic health records. medRxiv preprint April 2020. DOI: 10.1101/2020.04.11.20061994
18. Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID19 morbidity using electronic health records. medRxiv 2020: 2020.04.11.20061994. DOI: 10.1101/2020.04.11.20061994
19. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms. https://www.sciencealert.com/whorecommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms
20. Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ 2020; 369: m1555. DOI: 10.1136/bmj.m1555
21. Capuano A, Scaglione F, Berrino L et al. Official statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Nonsteroidal anti-infammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary. Pharmadvances 2020; 2 (1): 6–10. http://www.pharmadvances.com/official-statement-of-the-section-of-clinical-pharmacology-of-italian-s...
22. Zolk O, Hafner S, Schmidt CQ et al. COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. Naunyn Schmiedebergs Arch Pharmacol 2020; 393 (7): 1131–5. DOI: 10.1007/s00210-020-01890-6
23. EMA gives advice on the use of non-steroidal antiinflammatories for COVID-19. EMA/136850/2020. 18 March 2020. https://www.ema.europa.eu/en/documents/press-release/ema-gives-advice-use-non-steroidal-anti-inflamm...
Авторы
М.В. Леонова*
МОО «Ассоциация клинических фармакологов», Россия
*anti23@mail.ru
Association of Clinical Pharmacologists, Volgograd, Russia
*anti23@mail.ru
МОО «Ассоциация клинических фармакологов», Россия
*anti23@mail.ru
________________________________________________
Association of Clinical Pharmacologists, Volgograd, Russia
*anti23@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.